Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure
Gemcitabine is an intravenously administered nucleoside analog chemotherapeutic agent. The ability to deliver this agent as an oral drug would allow greater flexibility of administration and patient convenience; however, attempts have been fraught with high first-pass metabolism and potential intest...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2013-05-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1999-4923/5/2/261 |
| _version_ | 1798005957319458816 |
|---|---|
| author | Shannon Dow Richard Burton Richard Smith Jingqi Bao Enaksha Wickremsinhe Everett Perkins |
| author_facet | Shannon Dow Richard Burton Richard Smith Jingqi Bao Enaksha Wickremsinhe Everett Perkins |
| author_sort | Shannon Dow |
| collection | DOAJ |
| description | Gemcitabine is an intravenously administered nucleoside analog chemotherapeutic agent. The ability to deliver this agent as an oral drug would allow greater flexibility of administration and patient convenience; however, attempts have been fraught with high first-pass metabolism and potential intestinal toxicity. Alternatively, an amide prodrug of gemcitabine (LY2334737) was discovered, which is able to avoid the extensive first-pass metabolism that occurs following administration of gemcitabine. Preclinical in vitro and in vivo experiments were conducted to evaluate the hydrolysis and pharmacokinetics of LY2334737 and its downstream metabolites. In mice, rats, and dogs, the prodrug is absorbed largely intact across the intestinal epithelium and delivers LY2334737 to systemic circulation. The hydrolysis of LY2334737 is relatively slow, resulting in sustained release of gemcitabine in vivo. In vitro experiments identified carboxylesterase 2 (CES2) as a major enzyme involved in the hydrolysis of LY2334737, but with relatively low intrinsic clearance. Following hydrolysis of the prodrug, gemcitabine is cleared predominantly via the formation of its inactive metabolite dFdU. Both biliary and renal excretion was responsible for the elimination of LY2334737 and its metabolites in both mice and dogs. |
| first_indexed | 2024-04-11T12:47:17Z |
| format | Article |
| id | doaj.art-37461830edae46b790335d8cbbd71a37 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-04-11T12:47:17Z |
| publishDate | 2013-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-37461830edae46b790335d8cbbd71a372022-12-22T04:23:18ZengMDPI AGPharmaceutics1999-49232013-05-015226127610.3390/pharmaceutics5020261Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic ExposureShannon DowRichard BurtonRichard SmithJingqi BaoEnaksha WickremsinheEverett PerkinsGemcitabine is an intravenously administered nucleoside analog chemotherapeutic agent. The ability to deliver this agent as an oral drug would allow greater flexibility of administration and patient convenience; however, attempts have been fraught with high first-pass metabolism and potential intestinal toxicity. Alternatively, an amide prodrug of gemcitabine (LY2334737) was discovered, which is able to avoid the extensive first-pass metabolism that occurs following administration of gemcitabine. Preclinical in vitro and in vivo experiments were conducted to evaluate the hydrolysis and pharmacokinetics of LY2334737 and its downstream metabolites. In mice, rats, and dogs, the prodrug is absorbed largely intact across the intestinal epithelium and delivers LY2334737 to systemic circulation. The hydrolysis of LY2334737 is relatively slow, resulting in sustained release of gemcitabine in vivo. In vitro experiments identified carboxylesterase 2 (CES2) as a major enzyme involved in the hydrolysis of LY2334737, but with relatively low intrinsic clearance. Following hydrolysis of the prodrug, gemcitabine is cleared predominantly via the formation of its inactive metabolite dFdU. Both biliary and renal excretion was responsible for the elimination of LY2334737 and its metabolites in both mice and dogs.http://www.mdpi.com/1999-4923/5/2/261gemcitabineprodrugcarboxylesteraseCES2 |
| spellingShingle | Shannon Dow Richard Burton Richard Smith Jingqi Bao Enaksha Wickremsinhe Everett Perkins Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure Pharmaceutics gemcitabine prodrug carboxylesterase CES2 |
| title | Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure |
| title_full | Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure |
| title_fullStr | Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure |
| title_full_unstemmed | Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure |
| title_short | Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure |
| title_sort | preclinical absorption distribution metabolism and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure |
| topic | gemcitabine prodrug carboxylesterase CES2 |
| url | http://www.mdpi.com/1999-4923/5/2/261 |
| work_keys_str_mv | AT shannondow preclinicalabsorptiondistributionmetabolismandexcretionofanoralamideprodrugofgemcitabinedesignedtodeliverprolongedsystemicexposure AT richardburton preclinicalabsorptiondistributionmetabolismandexcretionofanoralamideprodrugofgemcitabinedesignedtodeliverprolongedsystemicexposure AT richardsmith preclinicalabsorptiondistributionmetabolismandexcretionofanoralamideprodrugofgemcitabinedesignedtodeliverprolongedsystemicexposure AT jingqibao preclinicalabsorptiondistributionmetabolismandexcretionofanoralamideprodrugofgemcitabinedesignedtodeliverprolongedsystemicexposure AT enakshawickremsinhe preclinicalabsorptiondistributionmetabolismandexcretionofanoralamideprodrugofgemcitabinedesignedtodeliverprolongedsystemicexposure AT everettperkins preclinicalabsorptiondistributionmetabolismandexcretionofanoralamideprodrugofgemcitabinedesignedtodeliverprolongedsystemicexposure |